Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): A multicentre, double-blind, randomised controlled trial

The Lancet Respiratory Medicine

Volumn 1, Issue 8, 2013, Pages 610-620

  Valery, Patricia C ^a   Morris, Peter S ^a,b   Byrnes, Catherine A ^c,d   Grimwood, Keith ^e,f   Torzillo, Paul J ^g,h   Bauert, Paul A ^b   Masters, I Brent ^e,f   Diaz, Abbey ^a   McCallum, Gabrielle B ^a   Mobberley, Charmaine ^c   Tjhung, Irene ⁱ   Hare, Kim M ^a   Ware, Robert S ^e   Chang, Anne B ^a,f,j  

^a MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^b ROYAL DARWIN HOSPITAL   (Australia)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

^d STARSHIP CHILDREN S HOSPITAL   (New Zealand)

^e UNIVERSITY OF QUEENSLAND   (Australia)

^f ROYAL CHILDREN'S HOSPITAL   (Australia)

^g UNIVERSITY OF SYDNEY   (Australia)

^h ROYAL PRINCE ALFRED HOSPITAL   (Australia)

ⁱ Torres Strait Northern Peninsula Hospital and Health Service   (Australia)

^j QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; PLACEBO; ANTIINFECTIVE AGENT;

ADOLESCENT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; AUSTRALIA; BACTERIUM CARRIER; BRONCHIECTASIS; CHILD; CHILD HEALTH CARE; CHRONIC DRUG ADMINISTRATION; CHRONIC SUPPURATIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; FEASIBILITY STUDY; FEMALE; HUMAN; INDIGENOUS PEOPLE; LUNG DISEASE; MALE; MAORI; MULTICENTER STUDY; NEW ZEALAND; NOSE SMEAR; PACIFIC ISLANDS; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; CHRONIC DISEASE; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECTS; EARLY TERMINATION OF CLINICAL TRIAL; ETHNOLOGY; HAEMOPHILUS INFLUENZAE; HETEROZYGOTE; INFANT; INTENTION TO TREAT ANALYSIS; LENGTH OF STAY; LUNG DISEASES; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MORAXELLA CATARRHALIS; NOSE; OCEANIC ANCESTRY GROUP; PATHOLOGY; PATIENT CARE; SEVERITY OF ILLNESS INDEX; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; SUPPURATION; TIME;

ANTI-BACTERIAL AGENTS; AUSTRALIA; AZITHROMYCIN; BRONCHIECTASIS; CARRIER STATE; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG RESISTANCE, BACTERIAL; EARLY TERMINATION OF CLINICAL TRIALS; EPISODE OF CARE; FEMALE; HAEMOPHILUS INFLUENZAE; HUMANS; INFANT; INTENTION TO TREAT ANALYSIS; LENGTH OF STAY; LUNG DISEASES; MALE; MICROBIAL SENSITIVITY TESTS; MORAXELLA (BRANHAMELLA) CATARRHALIS; NOSE; OCEANIC ANCESTRY GROUP; SEVERITY OF ILLNESS INDEX; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; SUPPURATION; TIME FACTORS;

EID: 84885039950     PISSN: 22132600     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-2600(13)70185-1     Document Type: Article

References (44)

1. Chang AB, Bell SC, Byrnes CA, et al. Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand. Med J Aust 2010, 193:356-365.
2. Chang AB, Marsh RL, Smith-Vaughan HC, Hoffman LR Emerging drugs for bronchiectasis. Expert Opin Emerg Drugs 2012, 17:361-378.
3. Kapur N, Masters IB, Chang AB Longitudinal growth and lung function in pediatric non-cystic fibrosis bronchiectasis: what influences lung function stability?. Chest 2010, 138:158-164.
4. Steinfort DP, Brady S, Weisinger HS, Einsiedel L Bronchiectasis in Central Australia: a young face to an old disease. Respir Med 2008, 102:574-578.
5. Grimwood K Airway microbiology and host defences in paediatric non-CF bronchiectasis. Paediatr Respir Rev 2011, 12:111-118.
6. Chalmers JD, Smith MP, McHugh BJ, Doherty C, Govan JR, Hill AT Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2012, 186:657-665.
7. Southern KW, Barker PM, Solis-Moya A, Patel L Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2011, 12. CD002203.
8. Masekela R, Green RJ The role of macrolides in childhood non-cystic fibrosis-related bronchiectasis. Mediators Inflamm 2012, 2012:134605.
9. Altenburg J, de Graaff CS, Stienstra Y, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA 2013, 309:1251-1259.
10. Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012, 380:660-667.
11. Shi W, Bellusci S, Warburton D Lung development and adult lung diseases. Chest 2007, 132:651-656.
12. Hare KM, Grimwood K, Leach AJ, et al. Respiratory bacterial pathogens in the nasopharynx and lower airways of Australian indigenous children with bronchiectasis. J Pediatr 2010, 157:1001-1005.
13. Valery P, Morris PS, Grimwood K, et al. Azithromycin for Indigenous children with bronchiectasis: study protocol for a multi-centre randomized controlled trial. BMC Pediatr 2012, 12:122.
14. Chang AB, Grimwood K, Maguire G, King PT, Morris PS, Torzillo PJ Management of bronchiectasis and chronic suppurative lung disease in indigenous children and adults from rural and remote Australian communities. Med J Aust 2008, 189:386-393.
15. Stockley RA, Bayley D, Hill SL, Hill AT, Crooks S, Campbell EJ Assessment of airway neutrophils by sputum colour: correlation with airways inflammation. Thorax 2001, 56:366-372.
16. Valery PC, Torzillo PJ, Mulholland K, Boyce NC, Purdie DM, Chang AB Hospital-based case-control study of bronchiectasis in indigenous children in Central Australia. Pediatr Infect Dis J 2004, 23:902-908.
17. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003, 290:1749-1756.
18. DiMatteo MR Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 2004, 42:200-209.
19. Modi AC, Lim CS, Yu N, Geller D, Wagner MH, Quittner AL A multi-method assessment of treatment adherence for children with cystic fibrosis. J Cyst Fibros 2006, 5:177-185.
20. Anwar GA, Bourke SC, Afolabi G, Middleton P, Ward C, Rutherford RM Effects of long-term low-dose azithromycin in patients with non-CF bronchiectasis. Respir Med 2008, 102:1494-1496.
21. Serisier DJ, Martin ML, McGuckin MA, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA 2013, 309:1260-1267.
22. Koh YY, Lee MH, Sun YH, Sung KW, Chae JH Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double-blind, placebo-controlled study. Eur Respir J 1997, 10:994-999.
23. Serisier DJ Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases. Lancet Respir Med 2013, 1:262-274.
24. Coles CL, Mabula K, Seidman JC, et al. Mass distribution of azithromycin for trachoma control is associated with increased risk of azithromycin-resistant Streptococcus pneumoniae carriage in young children 6 months after treatment. Clin Infect Dis 2013, 56:1519-1526.
25. Leach AJ, Shelby-James TM, Mayo M, et al. A prospective study of the impact of community-based azithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae. Clin Infect Dis 1997, 24:356-362.
26. Leach AJ, Morris PS, McCallum GB, et al. Emerging pneumococcal carriage serotypes in a high-risk population receiving universal 7-valent pneumococcal conjugate vaccine and 23-valent polysaccharide vaccine since 2001. BMC Infect Dis 2009, 9:121.
27. Nuermberger E, Bishai WR The clinical significance of macrolide-resistant Streptococcus pneumoniae: it's all relative. Clin Infect Dis 2004, 38:99-103.
28. Lonks JR, Garau J, Gomez L, et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 2002, 35:556-564.
29. Andrews RM, McCarthy J, Carapetis JR, Currie BJ Skin disorders, including pyoderma, scabies, and tinea infections. Pediatr Clin North Am 2009, 56:1421-1440.
30. Turnidge JD High burden of staphylococcal disease in indigenous communities. J Infect Dis 2009, 199:1416-1418.
31. Coles CL, Seidman JC, Levens J, Mkocha H, Munoz B, West S Association of mass treatment with azithromycin in trachoma-endemic communities with short-term reduced risk of diarrhea in young children. Am J Trop Med Hyg 2011, 85:691-696.
32. Keenan JD, Ayele B, Gebre T, et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clin Infect Dis 2011, 52:883-888.
33. Mick P, Westerberg BD Sensorineural hearing loss as a probable serious adverse drug reaction associated with low-dose oral azithromycin. J Otolaryngol 2007, 36:257-263.
34. Morris PS, Leach AJ, Silberberg P, et al. Otitis media in young Aboriginal children from remote communities in Northern and Central Australia: a cross-sectional survey. BMC Pediatr 2005, 5:27.
35. Binder AM, Adjemian J, Olivier KN, Prevots DR Epidemiology of nontuberculous mycobacterial infections and associated chronic macrolide use among persons with cystic fibrosis. Am J Respir Crit Care Med 2013, published online Aug 8. 10.1164/rccm.201307-1200OC.
36. Catherinot E, Roux AL, Vibet MA, et al. Inhaled therapies, azithromycin and Mycobacterium abscessus in cystic fibrosis patients. Eur Respir J 2013, 41:1101-1106.
37. Anderson I, Crengle S, Kamaka ML, Chen TH, Palafox N, Jackson-Pulver L Indigenous health in Australia, New Zealand, and the Pacific. Lancet 2006, 367:1775-1785.
38. Chang AB, Byrnes CA, Everard ML Diagnosing and preventing chronic suppurative lung disease (CSLD) and bronchiectasis. Paediatr Respir Rev 2011, 12:97-103.
39. Kapur N, Karadag B Differences and similarities in non-cystic fibrosis bronchiectasis between developing and affluent countries. Paediatr Respir Rev 2011, 12:91-96.
40. Trenholme AA, Byrnes CA, McBride C, et al. Respiratory health outcomes 1 year after admission with severe lower respiratory tract infection. Pediatr Pulmonol 2013, 48:772-779.
41. Matsuoka S, Uchiyama K, Shima H, Ueno N, Oish S, Nojiri Y Bronchoarterial ratio and bronchial wall thickness on high-resolution CT in asymptomatic subjects: correlation with age and smoking. AJR Am J Roentgenol 2003, 180:513-518.
42. Jung KJ, Lee KS, Kim SY, Kim TS, Pyeun YS, Lee JY Low-dose, volumetric helical CT: image quality, radiation dose, and usefulness for evaluation of bronchiectasis. Invest Radiol 2000, 35:557-563.
43. Kapur N, Masters IB, Morris PS, Galligan J, Ware R, Chang AB Defining pulmonary exacerbation in children with non-cystic fibrosis bronchiectasis. Pediatr Pulmonol 2012, 47:68-75.
44. Murray MP, Turnbull K, Macquarrie S, Hill AT Assessing response to treatment of exacerbations of bronchiectasis in adults. Eur Respir J 2009, 33:312-318.